The National Institute for Health and Care Excellence has recommended #Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritonealcancer in adults with a BRCA1 or BRCA2 mutation (see link below). NICE reported this endorsement is due to recent evidence from #clinicaltrials. Using #Kognitic‘s breadth of filters, our clients can access all Lynparza trials in this #patientsegment instantly!

#OvarianCancer #Olaparib #Cancer #Automation #AI #FallopianTubeCancer #PeritonealCancer #Mutation #DataAnalytics #Pharma #PARP

https://www.nice.org.uk/guidance/TA620